| Name | Title | Contact Details |
|---|
Fresenius SE & Co. KGaA is a health care company based in Bad Homburg vor der Höhe, Germany.
Keystone Peer Review Organization is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Patients vary in more ways than gender, race, and size. At Conformis, we believe that optimizing implant fit and performance requires a patient-specific approach. Our mission is to provide best-in-class, patient-specific implants and instrumentation that offer unique advantages over traditional orthopedic implants. We start with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. Our implants are individually sized and shaped to fit to each patient`s unique anatomy, providing precise anatomic fit and preserving healthy tissue. Our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. By combining our personalized implants with our unique instrumentation, a surgeon is able to provide a custom solution that preserves more of a patient`s joint and minimizes surgical trauma. Conformis, Inc. is a privately held medical device company based in Massachusetts. It was founded in 2004 to provide dramatic advancements in patient care by utilizing imaging technology to create personalized, patient-specific implants and instrumentation.
At Positive Development we empower children with autism and their families through the developmental model of autism therapy. Our developmental model respects the individuality of every child on the autism spectrum with treatment based on thei...
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.